Stick With LAMA Inhalers Instead of Nebulized Yupelri for Most COPD Patients

April 2019

You'll see Yupelri (yoo-PEL-ree, revefenacin), the first ONCE-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD.

It will have an edge over TWICE-daily Lonhala Magnair (glycopyrrolate)...the only other nebulized LAMA.

Yupelri is given via a standard nebulizer. Lonhala requires its own Magnair nebulizer...which can't be used to nebulize other meds.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Measles Address Measles Vaccine Concerns and Promote Immunization
Edema Evaluate Whether Peripheral Edema Is Due to Meds
Migraine Consider Triptans for Kids With Migraines
Anxiety Think of Buspirone as a Second- or Third-Line Option for Managing Anxiety
Osteoarthritis Weigh Benefits and Risks of Intra-Articular Injections for Osteoarthritis
Ulcerative Colitis Sort Through Treatments for Ulcerative Colitis
COPD Stick With LAMA Inhalers Instead of Nebulized Yupelri for Most COPD Patients
Hyperkalemia Don't Jump to Potassium Binders When ACEIs or ARBs Cause Hyperkalemia
Oral Health Stick With a Simple Formula if You Prescribe Magic Mouthwash
Veterinary Medicine Keep Pet Rxs in Mind as Another Source of Controlled Substance Diversion